Vimarsana
Biggest News Aggregation in the World

Page 3 - Simcere Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simcere Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simcere Pharmaceutical Today - Breaking & Trending Today

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue - Vimarsana News

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As of June 30, Simcere recorded...

Could Covid Drugs Help Cure Financial Ills At Ascletis Pharma? (undefined:ASCLF) - Vimarsana News

Could Covid Drugs Help Cure Financial Ills At Ascletis Pharma? (undefined:ASCLF)

Ascletis Pharma (ASCLF) is ready to put its new Covid drug into clinical trials, but the firm is lagging in the race to bring similar medicines to market. Read more.

Worldwide Healthcare Trust Plc - Audited Results for the year ended 31 March 2022 - Vimarsana News

Worldwide Healthcare Trust Plc - Audited Results for the year ended 31 March 2022

Worldwide Healthcare Trust Plc - Audited Results for the year ended 31 March 2022 PR Newswire London, May 27 LONDON STOCK EXCHANGE ANNOUNCEMENT Worldwide Healthcare

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day - Vimarsana News

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day

/PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for...

Kazia Therapeutics Ltd eyeing commercialisation revenue after "game-changing" FY21 - Vimarsana News

Kazia Therapeutics Ltd eyeing commercialisation revenue after "game-changing" FY21

Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.